AHI Commentary for the Quarter Ended 30 June 2023
- AHI has expanded partner opportunities in the UAE and received a $5 million placement at a market premium, indicating strong investor confidence. The company has significantly reduced its debt and consolidated post-acquisition operating costs by $4.8 million per annum. AHI has seen a strong uplift in NASDAQ trading. AHI is actively engaging in constructive dialogues to explore collaboration opportunities with various organizations within the healthcare technology industry.
- None.
Highlights
- Expanded Partner Opportunities in the UAE.
- AHI commenced Stellenbosch University joint study.
- AHI entered US FDA submissions.
- AHI clears NASDAQ Compliance Requirements.
- AHI received
$5m placement completed at a Market Premium.
- Significantly reduced Debt.
- Revenue of
$241,542 for quarter ending 30 June 2023.
- AHI consolidates post - acquisition operating cost by
$4.8 million per annum.
- Strong uplift in NASDAQ trading.
South Perth, Western Australia--(Newsfile Corp. - August 1, 2023) - Advanced Health Intelligence Ltd (ASX: AHI) (NASDAQ: AHI) ('AHI' or 'the Company'), is pleased to update shareholders regarding the attached Appendix 4C and to provide an update on its activities for the quarter ended 30 June 2023, along with additional partnerships the Company progressed during that quarter.
The Company's new capabilities are being well received by the market and are already showing strong demand from current and new partnerships. As previously outlined in the Company's Q3 Commentary and Appendix 4C.
During Q2 2023, AHI successfully optimized the integration process of its cutting-edge technology, facilitating demonstrations of our advanced solutions. Notably, our technology garnered significant attention and recognition, leading to an invitation from Boston Consulting Group ('BCG') Singapore to showcase our capabilities at their global summit on 10 May 2023.
During the BCG event, AHI's technology generated exceptional interest, resulting in long queues of attendees eagerly waiting to experience our groundbreaking scanning process. The overwhelming response served as a testament to the efficacy and appeal of our offerings.
Moreover, AHI's participation in the BCG summit opened up numerous discussions with potential partners across the region. As a result, AHI is actively engaging in constructive dialogues to explore collaboration opportunities with various organizations within the healthcare technology industry.
The success of AHI's technology demonstrations and the substantial interest expressed by industry leaders and attendees further strengthens AHI's position as a prominent player in the healthcare technology sector.
AHI has successfully undergone a transformative evolution, transitioning from its original focus on body scanning for dimension and composition assessment to become a comprehensive provider of biometric health risk assessment ('BHA') solutions.
This strategic shift has been undertaken to cater to a broader audience encompassing various sectors such as Healthcare, Insurance, population health, Non-Government Organizations (NGO), and Health Maintenance Organizations (HMO).
As part of this transformation, AHI now offers a fully-fledged suite of scalable health assessment, risk stratification, and digital triage services to healthcare providers, insurers, employers, and government agencies. These unique and proprietary capabilities are designed to facilitate cost-effective health accessibility, empowering smartphone users to proactively manage and improve their overall health outcomes.
To enhance accessibility and streamline adoption, AHI has introduced partner-friendly delivery methods. These options include white-label applications, URL-based integration, web-based applications, as well as the traditional Software Development Kit (SDK) that AHI previously provided. By offering multiple delivery channels, AHI aims to minimize friction and reduce time-to-market for its valuable partners.
This comprehensive approach to biometric health risk assessment marks an important milestone in AHI's journey to serve a diverse range of industries and stakeholders, driving positive health outcomes for individuals and contributing to the advancement of healthcare accessibility on a global scale.
All of this will assist AHI in increasing revenue within current partnerships and unlocking multiple partnership approaches.
As AHI scales its partner and commercial pipeline it's also identifying cost consolidation opportunities with new operating models. Since the completion of two acquisitions in 2022, AHI has consolidated its operating model including its team and tools of business, and in doing so has reduced its annual cost base by over
Vlado Bosanac, Founder and Head of Strategy at AHI, said:
"The Company has achieved strong commercial and financial progress over the past fiscal period. Through strategic initiatives and prudent management, AHI has successfully strengthened its financial position and improved its market standing. AHI experienced unprecedented trading on the NASDAQ throughout June and July with gross ADR volume trading reaching well over 300,000,000 traded ADR's, from an original ADR base of only 2,565,688 ADR's.
One of the significant accomplishments during this period has been the substantial reduction of convertible note debt. Through additional management strategies and cash flow optimization, AHI has significantly lowered its debt levels, which not only enhances its financial stability but demonstrates the Company's commitment to responsible financial practices.
AHI also announced the conclusion of a successful capital raising which saw
Scott Montgomery, CEO at AHI, said:
"AHI is demonstrating performances as one of the most exciting publicly-traded technology companies globally - evidenced by trade volumes of its ADRs on the NASDAQ this last two months. The fast maturing of AHI's business operations following the acquisitions in 2022 is resonating with the investor community, and it appears recognising the strategic positioning of bringing biometric health measures to smartphone users globally as a worthwhile opportunity.
"The Company is consistently executing on its strategic plan and is a small number of commercial contracts away from cashflow breakeven, whilst continuing to invest in its IP portfolio, validation studies with world-class universities and pursuit of regulator accreditations."
Commercial update
AHI is delighted to provide a partner update that highlights our ongoing dedication to serving existing partners through our advanced technologies. Simultaneously, AHI is excited to introduce its latest biometric health assessment, a cutting-edge solution that opens up new opportunities for expanding existing collaborations and establishing new commercial partnerships.
AHI is diligently working with our current partners, ensuring that they continue to receive support and access to our state-of-the-art technologies.
As demonstrated by the recent signing of Pharmak LLC in the UAE, we are actively seeking new partners and opening in new regions to achieve global reach of our technology in the healthcare sector. By forging strategic alliances with like-minded organizations, AHI aims to make a significant impact on the industry while delivering innovation and validated advancements in healthcare practices.
On 13 June 2023, AHI announced that it had agreed to issue Orca Capital GMBH, an offshore institutional investor, 20,000,000 fully paid ordinary shares, raising A
AHI will use the net proceeds received from this offering primarily for the Company's current products and business development and marketing, with the remainder of the proceeds to be used for general corporate purposes, including, without limitation, investing in or acquiring companies that are synergistic with or complimentary to our technologies and working capital.
The offering represents a
AHI is currently in negotiations with parties looking to participate in the balance of the convertible note round. AHI will keep shareholders informed as this round of fund-raising progresses.
On 26 June 2023 AHI informed shareholders that the Company had received a determination letter from Nasdaq stating that the Company has not regained compliance with the Nasdaq Rules.
The Company took the necessary steps to immediately effect a ratio change of the ADSs to its non-traded ordinary shares from the current ratio of one (1) ADS representing seven (7) ordinary shares to a new ratio which will have the same effect as a reverse split of the existing ADSs.
On 30 June 2023, AHI announced that its planned ratio change of the Company's American Depositary Shares (ADSs) to its non-traded ordinary shares from the previous ratio of one (1) ADS representing seven (7) ordinary shares to the new ratio of one (1) ADS representing twenty-eight (28) ordinary shares shall become effective on 30 June 2023. The ratio change has the same effect as a reverse split of the existing ADSs of 1 new ADS for every 4 old ADSs. The effective date for the ratio change is 29 June 2023, and the Company's ADSs continued to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "AHI" with a new CUSIP Number 00777C 203.
On 14 July 2023, the Company advised the market that as the Company's ratio change has taken effect, the ADSs have traded well above the USD
Expected Commercial Partner Launches in Q3 2023
Upvio Healthtech.
Telehealth platform Upvio Healthtech is expected to launch in Q3 2023.
Upvio offers comprehensive medical, health and wellness practitioners technology, including human imaging, feature-rich appointment scheduling, digital forms, video calls, virtual waiting rooms, asynchronous and synchronous chat, a patient portal, and the ability to integrate into existing software. Upvio enables geo-cloud storage for securely storing sensitive patient information, ensuring that patients' data is always kept safe and secure. Upvio aims to be the first telehealth platform in the world with in-built contactless human imaging tools that can provide a scientifically validated health risk assessment in real-time.
This is a game-changing development, as it means that healthcare professionals can now obtain an accurate picture of a patient's health and risk status more easily, conveniently, and affordably without the need for physical contact, drastically reducing the risk of malpractice. The platform is built on a digital-first ethos, with both patients and healthcare professionals in mind. It brings together the best-of-breed technologies, including AHI's scanning and risk assessment capabilities.
AHI does not expect to generate revenue from Upvio until it has commercially launched.
Augmented Reality Concierge LLC ("ARC")
US-based Augmented Reality Concierge LLC whilst experiencing minor delays in the expected Q2 2023 Launch, is now expected to Launch in August 2023.
Augmented Reality Concierge, LLC is a unique company that builds and implements state-of-the-art applications that empower consumers and companies to simplify and enhance their surroundings whilst improving the lives of their consumers. Using the latest proprietary, innovative technologies, the ARC's creative tools are fun and exciting, allowing people to engage with them to realise their goals.
The ARC was created in 2019 to build a fitness application that uses augmented reality navigation to guide users in the gym and show them what to do and how to do it based on each gym's specific equipment range. During this time, the ARC realised that the technology would solve similar problems confronting universities, airports, malls, grocery stores, and theme parks, to mention a few. The ARC then went a step further and designed a true "concierge" concept that caters to a company's or its consumer's wants or needs.
AHI does not expect to generate revenue until Augmented Reality Concierge has commercially launched.
Subsequent events and funding progress update
On 5 July 2023, AHI updated shareholders regarding several initiatives the Company had undertaken.
Stellenbosch Study
AHI is dedicated to ensuring the effectiveness and accuracy of our proprietary multi-sensor data set captured via the BHA. AHI has initiated a joint study with renowned Stellenbosch University to rigorously test and evaluate the capabilities of AHI's BHA. This technology utilizes a contactless method on smartphones, producing 61 health outputs across five significant health and disease categories: cardio-respiratory, body composition, estimated blood biomarkers, metabolic health, and mental health.
Stellenbosch University, known for exceptional research history and healthcare expertise, is an ideal collaborator for this study. Their scientific rigor and reputation bring invaluable insights to verify our biometrically driven outputs, captured and computed using four sensors exclusively on smartphones-no additional equipment or medical professionals required.
Significant progress has been made in the initial phase of the study, testing AHI's BHA on the first 20 subjects, yielding valuable correlative biometric data sets and promising results. Across these subjects, 18 showed clinical relevance, affirming the efficacy of our technology in stratifying biometric health risk through non-invasive and contactless methods.
This achievement highlights the robustness and reliability of our sensor set, enhancing confidence in the transformative potential of our smartphone-based biometric health assessment. The collaboration with Stellenbosch University further strengthens the credibility and reliability of our technology, instilling confidence in the broader healthcare community.
As the study progresses, we maintain the highest scientific rigor, aiming to establish a solid foundation for global implementation and adoption of our multi-sensor capture. This collaborative effort will contribute to shaping the future of healthcare and reaffirm our position as a trusted provider of cutting-edge health technology solutions.
FDA Submissions Underway
AHI has made an initial submission to the FDA by section 513(g). The purpose of a Section 513(g) submission is to obtain clarification on the regulatory pathway for a medical device. This will provide AHI with the appropriate guidance from the FDA before submitting a formal application. The FDA is currently reviewing the request and AHI is awaiting written feedback.
The current submission is seeking categorisation of the AHI BodyScan to be specifically used in the identification and tracking of obesity. AHI's long-term strategy to seek FDA approval for the BHA under a 510K software as a medical device category. The Stellenbosch study will provide valuable data that will form part of these submissions.
Why AHI developed the Biometric Health Assessment ('BHA')
AHI's BHA is a powerful solution for healthcare, insurers, and governments, revolutionizing patient care. Based on extensive medical literature and studies, AHI has digitized trusted health indicators used by medical professionals, significantly reducing human error.
The BHA enables accurate, low-cost data accessible to most smartphone users worldwide. Early detection of chronic diseases like cardiovascular conditions, diabetes, respiratory disorders, sleep apnea, and mental health issues is crucial for individuals and healthcare systems. Traditional physician-led screening can delay access to overburdened professionals and cause financial strain on payors.
By analysing biometric data, including vital signs, body fat, and blood lipid profiles, our BHA helps identify early warning signs before visible symptoms appear. This proactive approach allows timely interventions, such as lifestyle modifications and targeted treatments, leading to improved outcomes and substantial cost savings.
Early intervention with the BHA can save billions in healthcare costs, reducing hospitalizations and expensive treatments. Resources can be allocated to preventive care and community health initiatives, creating a sustainable healthcare system.
AHI's BHA empowers healthcare professionals with a reliable, digitized tool for early disease risk identification and intervention. By harnessing proven scientific principles through smartphone access, AHI's BHA transforms patient care and fosters a cost-effective healthcare system for all stakeholders.
Partnership review undertaken
AHI reviewed all partnerships over Q2 2023. taking into consideration partner fit, delays, and AHI's direction. This resulted in AHI removing a number of partnerships as follows. FitTrack Incorporated, Jayex Health, eMersion Technology due to delays in integration or market entry. AHI is happy to continue with these organisations when they have progressed their platform and commercial position. AHI has not elected to seek an extension of its contract with Bupa Australia for corporate wellness step challenges. This contract will complete its term on 31 July 2023. Further to the outlined organisations, AHI and NextMedical SAC terminated the MSA due to it becoming insolvent. AHI and NextMedical shared a strong relationship and AHI remains committed to assisting NextMedical once the company has undertaken its restructure and recapitalisation.
Funding update
At 30 June 2023, AHI had a closing cash balance of
Subsequent to the quarter ended 30 June 2023, AHI has been presented with three additional funding proposals of between
The Board of Advanced Health Intelligence Ltd has approved this announcement.
For more information, contact:
Scott Montgomery
Chief Executive Officer
Advanced Health Intelligence Ltd
E: admin@ahi.tech
Vlado Bosanac
Founder/Head of Strategy
Advanced Health Intelligence Ltd
E: admin@ahi.tech
Cautionary Note Regarding Forward-Looking Statements:
This news release contains information or statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.
Forward-looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies, and outlook of Advance Health Intelligence, and includes statements about, among other things, future developments and the future operations, strengths, and strategies of Advance Health Intelligence. Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results.
The forward-looking statements made, or perceived to be made, in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analysis, and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavorable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for Advanced Health Intelligence's products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions.
The forward-looking information contained in this news release represents the expectations of Advance Health Intelligence as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Advance Health Intelligence undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/175638
FAQ
What are the recent achievements of AHI?
What is AHI's revenue for the quarter ending 30 June 2023?
What is AHI's current focus?
